Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-27), Orchid Pharma's 9-Day RSI is 46.07.
The industry rank for Orchid Pharma's 9-Day RSI or its related term are showing as below:
BOM:524372's 9-Day RSI is ranked worse than 57.31% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 44.43
vs BOM:524372: 46.07
Orchid Pharma (BOM:524372) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Orchid Pharma 9-Day RSI Related Terms
BOM:524372 vs ZTS: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchid Pharma (BOM:524372) has a 9-Day RSI of 46.07 as of Jul. 27, 2026. According to the industry distribution chart, Orchid Pharma ranks #600 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 57.3%.
Is Orchid Pharma's 9-Day RSI too high?
Orchid Pharma's current 9-Day RSI is 46.07. The Drug Manufacturers industry median 9-Day RSI is 44.43. Orchid Pharma's value of 46.07 is 3.7% above this industry median. Based on the distribution chart, Orchid Pharma ranks #600 out of 1047 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orchid Pharma has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's 9-Day RSI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orchid Pharma ranks #600 out of 1047 companies for 9-Day RSI. This places Orchid Pharma in the lower half of its industry. The industry median 9-Day RSI is 44.43. Orchid Pharma's value of 46.07 is 3.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 44.43, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchid Pharma's current 9-Day RSI of 46.07 is 3.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 44.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchid Pharma's current 9-Day RSI is 46.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orchid Pharma (BOM:524372) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹848.44, compared to a current price of ₹986.30 — trading 16.2% above its estimated fair value. The current 9-Day RSI is 46.07 and 3.7% above the Drug Manufacturers industry median of 44.43. Orchid Pharma's overall GF Score™ is 58/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Orchid Pharma (BOM:524372), the current 9-Day RSI is 46.07 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchid Pharma (BOM:524372) Overvalued in 2026?
Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued.
The current stock price of ₹986.30 is trading 16.2% above its estimated GF Value™ of ₹848.44.
GuruFocus considers Orchid Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524372:
9-Day RSI: 46.07
GF Value™: ₹848.44 vs. price of ₹986.30 (16.2% above fair value)
Industry Position: 3.7% above the Drug Manufacturers median (#600 of 1047)
No single metric tells the full story. See the BOM:524372 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
58GF Score
Get the complete analysis for BOM:524372
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524372 has been successfully added to your 
